Recombinant Human Anti-IAV HA Antibody (CT149) (CAT#: PABL-213)

Figure 1 Recombinant Human Anti-IAV HA Antibody (PABL-213) in SDS-PAGE

SDS-PAGE analysis of PABL-213 in non-reduced (Lane 1, 2 μg) and β-mercaptoethanol-reduced (Lane 2, 2 μg) conditions.

Figure 2 Recombinant Human Anti-IAV HA Antibody (PABL-213) in HPLC

The purity of PABL-213 was greater than 95% as determined by SEC-HPLC.

Figure 3 Anti-IAV HA Recombinant Antibody (PABL-213) in ELISA

ELISA analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-213. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 4 Anti-IAV HA Recombinant Antibody (PABL-213) in ELISA

ELISA analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-213. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Anti-IAV HA Recombinant Antibody (PABL-213) in WB

Western blot analysis of PABL-213 was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 6 Anti-IAV HA Recombinant Antibody (PABL-213) in WB

Western blot analysis of PABL-213 was performed with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 7 Anti-IAV HA Recombinant Antibody (PABL-213) in WB

Western blot analysis of PABL-213 was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 8 Anti-IAV HA Recombinant Antibody (PABL-213) in DB

Dot Blot analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).

PABL-213 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)

Figure 9 Anti-IAV HA Recombinant Antibody (PABL-213) in DB

Dot Blot analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).

PABL-213 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)